On the public citation graph
Effectiveness and Safety of Apatinib in Patients with Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction: A Prospective Observation Study
0 signed · 26 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/ijc.28829openalex-snapshot
Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer
inferredcites →https://doi.org/10.1016/j.bcp.2011.12.007openalex-snapshot
Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells
inferredcites →https://doi.org/10.1016/j.canlet.2016.01.014openalex-snapshot
Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer
inferredcites →https://doi.org/10.1016/j.cllc.2018.06.002openalex-snapshot
A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non–small-cell Lung Cancer
inferredcites →https://doi.org/10.1038/bjc.2011.2openalex-snapshot
Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
inferredcites →https://doi.org/10.1038/nm0603-669openalex-snapshot
The biology of VEGF and its receptors
inferredcites →https://doi.org/10.1038/s41598-017-13192-8openalex-snapshot
Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study
inferredcites →https://doi.org/10.1093/annonc/mds145openalex-snapshot
Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study
inferredcites →https://doi.org/10.1093/annonc/mds179openalex-snapshot
Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib
inferredcites →https://doi.org/10.1093/annonc/mdz394.034openalex-snapshot
Randomized phase III ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens
inferredcites →https://doi.org/10.1200/jco.2013.48.8585openalex-snapshot
Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
inferredcites →https://doi.org/10.1200/jco.2014.60.1799openalex-snapshot
Update on Metastatic Gastric and Esophageal Cancers
inferredcites →https://doi.org/10.1200/jco.2015.63.5995openalex-snapshot
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
inferredcites →https://doi.org/10.3322/caac.21492openalex-snapshot
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
inferredcites →https://doi.org/10.3978/j.issn.2305-5839.2014.08.14openalex-snapshot
Clinical advances in the development of novel VEGFR2 inhibitors.
inferredcites →https://doi.org/10.7150/jca.26376openalex-snapshot
The Efficacy and Safety of Apatinib Treatment for Patients with Unresectable or Relapsed Liver Cancer: a retrospective study
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.5016626openalex-extracted
Vasculopathy in the Correa's Cascade of Gastric Cancer: Pathological Features and Phytotherapy Strategy
inferred← citeshttps://doi.org/10.1177/17588359221110176openalex-snapshot
Tumor vessel normalization and immunotherapy in gastric cancer
inferred← citeshttps://doi.org/10.1186/s12885-024-12832-3openalex-snapshot
Characteristics and patient-reported outcomes of long-term cancer survivors after apatinib-based therapy: an online survey
inferred← citeshttps://doi.org/10.21037/atm-22-2752openalex-snapshot
Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study
inferred← citeshttps://doi.org/10.21037/atm-22-546openalex-snapshot
Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study
inferred← citeshttps://doi.org/10.21037/atm-22-5995openalex-snapshot
Apatinib in the treatment of gastric cancer in Henan Province: a multicenter prospective real-world observational study (Ahead-HAP01)
inferred← citeshttps://doi.org/10.21037/jgo-22-727openalex-snapshot
Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: a sub-analysis from the large-scale, prospective observational study of apatinib for gastric cancer treatment in a real-world clinical setting (AHEAD-G202)
inferred← citeshttps://doi.org/10.3389/fonc.2021.749083openalex-snapshot
Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review
inferred← citeshttps://doi.org/10.3389/fonc.2023.1148131openalex-snapshot
Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.